Post-war rationing in the UK in 1953 facilitated a natural experiment that now reveals that restricting sugar intake in early life reduces the risk of diabetes and hypertension.

Addendum to: Nature Medicine https://doi.org/10.1038/nm1161, published online 26 December 2004.

Correction to: Nature Medicine https://doi.org/10.1038/s41591-024-03076-6, published online 17 June 2024.

As GLP-1 receptor agonists emerge as treatment options for conditions beyond diabetes and obesity, it becomes critical to understand how genetic, clinical and sociodemographic differences impact their effects on weight loss.

Two studies reveal high transmissibility and lethality of the viral isolate in animal models, and hint at potential drug susceptibility — but further analysis and ongoing surveillance of infections will be critical for public health.

Climate Change has severe and wide-ranging health impacts, especially for vulnerable groups. Despite growing evidence of heat-associated adverse maternal and neonatal health outcomes, there remains a lack of synthesis quantifying associations and identifying specific risk periods. We systematically reviewed the literature on heat impacts on maternal, fetal, and neonatal health, and quantified impacts

The twentieth century saw unprecedented rises in life expectancy in high-income countries, but data suggest that this trend will not continue in the current century without radical interventions to slow biological aging.

In British South Asian women, a culturally adapted and community-informed cognitive behavioral therapy intervention led to higher early recovery rates than the usual treatment.

Correction to: Nature Medicine https://doi.org/10.1038/s41591-024-03264-4, published online 1 September 2024.

The current Oropouche fever outbreak has been traced to a novel reassortant virus that emerged about a decade ago, which highlights the importance of One Health surveillance in preventing, predicting, detecting and responding to emerging threats.

Monkeypox virus (MPXV) is endemic in Western and Central Africa and, in May 2022, a clade IIb lineage (B.1) caused a global outbreak outside Africa, resulting in its detection in 116 countries/territories. To understand the global phylogenetics of MPXV, we analysed all available MPXV sequences, including 10,670 sequences from 65 countries collected between 1958 and 2024. Our analysis reveals high mobility

Correction to: Nature Medicine https://doi.org/10.1038/nm.4047, published online 15 February 2016.

Google’s development of MedLM found that risk management processes were an essential tool to protect patient safety.

In the USA, there are more than 5.5 million registered patients in state-regulated medicinal cannabis programs and many people use hemp products (sourced from cannabis containing <0.3% delta-9-tetrahydrocannabinol (THC) by dry weight) for therapeutic purposes. However, clinical research on non-pharmaceutical cannabis products remains limited1, healthcare providers feel inadequately trained on integrating

Two new studies characterize the unequal global burden of avoidable mortality and the economic value of reducing it — providing evidence to support targeted investment in health and longevity.

The deployment of artificial intelligence (AI)-powered prediction models in healthcare can lead to ethical concerns about their implementation and upscaling. For example, AI prediction models can hinder clinical decision-making if they advise different diagnoses or treatments by sex and gender or by race and ethnicity without clear justification. Recent guidance (such as the WHO guidance on ethics

A large study failed to show a reduction in gastric cancer incidence or mortality when Helicobacter pylori screening was added to standard colon cancer screening.

Many lessons have been learned 10 years after the Ebola virus disease outbreak in West Africa, but urgent work is now needed to prevent another outbreak.

In the NIAGARA trial, the addition of perioperative durvalumab to standard treatment for muscle-invasive bladder cancer improved event-free and overall survival, marking a new treatment option for this condition.

Correction to: Nature Medicine https://doi.org/10.1038/s41591-024-03282-2, published online 1 October 2024.

Artificial intelligence (AI) continues to show its potential for innovation in healthcare. As this transformation occurs, robust methods are needed to assess when and how AI should function autonomously. The scalability of AI use in healthcare will often conflict with the maintenance of human oversight, and an appropriate balance must be sought. We draw on ongoing debates in the military domain to

A study of over 2,000 people shows that interacting with a large language model reduced belief in conspiracy theories — including some related to COVID-19 — by providing tailored, one-on-one interactions and compelling evidence.

Increases in antimicrobial resistance globally are likely to hit African countries the hardest. Strengthening the local infrastructure aimed at combating infection is the only way to counter it.

Delandistrogene moxeparvovec received FDA approval after a negative trial, which highlights the many complexities and challenges of drug development in this setting.

The recent publication ‘A new framework for the diagnosis, staging and management of obesity in adults’ by authors from the European Association for the Study of Obesity1 illustrates a practical context for the diagnosis and treatment of obesity in adults. The document paves the way for more tailored assessment and treatment of obesity in adults. Although the authors deliberately focused on obesity

Plastics have become deeply integrated into human society and the economy but are polluting the environment. Plastic-associated chemicals enter the human body, and there are also reports of micro- and nanoplastics (MNPs) in human organs1,2. There is already a considerable and robust body of evidence on the adverse health impacts of plastic-associated chemicals3, including those in MNPs, and therefore

Biological aging clocks are flawed concepts in understanding disease.

Pharmaceutical companies are investing in therapies that target proteins for degradation, with trials ongoing for cancer, autoimmune diseases and neurological disorders.

Correction to: Nature Medicine https://doi.org/10.1038/s41591-023-02565-4, published online 14 September 2023.